Dietrich A. Stephan - Mar 16, 2023 Form 4 Insider Report for NeuBase Therapeutics, Inc. (NBSE)

Role
CEO and Director, Director, 10%+ Owner
Signature
/s/ Dietrich A. Stephan
Stock symbol
NBSE
Transactions as of
Mar 16, 2023
Transactions value $
$0
Form type
4
Date filed
3/17/2023, 04:11 PM
Previous filing
Feb 15, 2023
Next filing
Aug 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBSE Common stock Award $0 +153K $0.00 153K Mar 16, 2023 Direct F1
holding NBSE Common stock 1.47M Mar 16, 2023 Direct F2
holding NBSE Common stock 1.27M Mar 16, 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units to be settled by the issuance of one share of common stock for each restricted stock unit that is earned; 25% of which shall vest on March 16, 2024 and the remainder of which shall vest monthly thereafter until March 16, 2027, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Restricted stock units are subject to accelerated vesting, subject to certain conditions, in the event of a change of control of the Issuer.
F2 Shares held by the reporting person as a tenant by the entirety with his spouse.
F3 These shares are held in an irrevocable trust in which the spouse of the reporting person is the investment trustee, and the spouse and the descendants of the reporting person are its beneficiaries, and another irrevocable trust in which the reporting person is the investment trustee, and the reporting person and the descendants of the reporting person's spouse are its beneficiaries.